Cardiovascular risk in patients with Cushing’s syndrome

Česká verzia

Authors: T. Brutvan; J. Ježková
Authors place of work: III. interní klinika 1. LF UK a VFN v Praze
Published in the journal: Kardiol Rev Int Med 2018, 20(3): 185-187

Summary

Cushing’s syndrome is associated with higher morbidity and mortality rates, due mostly to cardiovascular complications. Cushing’s syndrome is caused by the prolonged, excessive and autonomous secretion of cortisol. Hypercortisolism leads to the development of metabolic disorders (visceral obesity, from impairment of glucose tolerance to diabetes mellitus, dyslipidaemia), arterial hypertension and thrombophilia; i.e. comorbidities leading to increased cardiovascular risk. Given the severity of the disease, it is important not to just treat the hypercortisolism, but also all the associated comorbidities, as the increased cardiovascular risk persists for a long time after the successful treatment of Cushing’s syndrome.

Key words:

Cushing’s syndrome – hypercortisolism – metabolic syndrome – cardiovascular risk

Zdroje

1. Lahera Vargas M, da Costa CV. Prevalence, etiology and clinical findings of Cushing's syndrome. Endocrinol Nutr 2009; 56(1): 32– 39. doi: 10.1016/ S1575-0922(09)70191-3.

2. Ganong WF. Přehled lékařské fyziologie. 20. vyd. Praha: Galén 2015.

3. Pivonello R, Faggiano A, Lombardi G et al. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 2005; 34(2): 327– 339. doi: 10.1016/ j.ecl.2005.01.010.

4. Pivonello R, De Martino MC, De Leo M et al. Cushing's syndrome. Endocrinol Metab Clin North Am 2008; 37(1): 135– 149. doi: 10.1016/ j.ecl.2007.10.010.

5. Chanson P, Salenave S. Metabolic syndrome in Cushing's syndrome. Neuroendocrinology 2010; 92 (Suppl 1): 96– 101. doi: 10.1159/ 000314272.

6. Hassan-Smith ZK, Sherlock M, Reulen RC et al. Outcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab 2012; 97(4): 1194– 1201. doi: 10.1210/ jc.2011-2957.

7. Pivonello R, Isidori AM, De Martino MC et al. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol 2016; 4(7): 611– 629. doi: 10.1016/ S2213-8587(16)00086-3.

8. Extabe J, Vazquez JA. Morbidity and mortality in Cushing's disease an epidemiological approach. Clin Endocrinol (Oxf) 1994; 40: 479– 481. doi: 10.1111/ j.1365-2265.1994.tb02486.x.

9. Faggiano A, Pivonello R, Spiezia S et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88(6): 2527– 2533. doi: 10.1210/ jc.2002-021558.

10. Colao A, Pivonello R, Spiezia S et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84(8): 2664– 2672. doi: 10.1210/ jcem.84.8.5896.

11. Ferrau F, Korbonits M. Metabolic comorbidities in Cushing's syndrome. Eur J Endocrinol 2015; 173(4): M133– M157. doi: 10.1530/ EJE-15-0354.

12. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009; 39(2): 81– 93. doi: 10.1111/ j.1365-2362.2008.02067.x.

13. Seino S, Shibasaki T, Minami K. Pancreatic beta-cell signaling: toward better understanding of diabetes and its treatment. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86(6): 563– 577. doi: 10.2183/ pjab.86.563.

14. Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88(12): 5593– 5602. doi: 10.1210/ jc.2003-030871.

15. Feelders RA, Pulgar SJ, Kempel A et al. The burden of Cushing's disease: clinical and health-related quality of life aspects. Eur J Endocrinol 2012; 167(3): 311– 326. doi: 10.1530/ EJE-11-1095.

16. Toja PM, Branzi G, Ciambellotti F et al. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure. Clin Endocrinol (Oxf) 2012; 76(3): 332– 338. doi: 10.1111/ j.1365-2265.2011.04206.x.

17. Miljic P, Miljic D, Cain JW et al. Pathogenesis of vascular complications in Cushing's syndrome. Hormones (Athens) 2012; 11(1): 21– 30.

18. van der Pas R, Leebek FN, Hofland LJ et al. Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 2013; 78(4): 481– 488. doi: 10.1111/ cen.12094.

19. Naess IA, Christiansen SC, Romundstad P et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5(4): 692– 699. doi: 10.1111/ j.1538-7836.2007.02450.x.

20. Stuijver DJ, van Zaane B, Feelders RA et al. Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab 2011; 96(11): 3525– 3532. doi: 10.1210/ jc.2011-1661.